Lineage Cell Therapeutics

LCTX Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-05

Catalyst timeline

COR1 readout2026COR1 readout, 2026, notable
LCTX corporate update3Q 2026LCTX corporate update, 3Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

OpRegen

RG6501

Cell Target: retinal pigmented epithelial cells

Geographic Atrophy Phase 2 Phase 1/2a trial subretinal Roche

OPC1

Cell Target: oligodendrocyte progenitor cells

Spinal Cord Injury Phase 1 Phase 1/2 trial NCT01217008
Undisclosed indication Preclinical

ReSonance

ANP1

Cell Target: auditory neuron progenitor cells

Auditory Neuropathy Preclinical William Demant Invest 2 Aps
Sensorineural Hearing Loss Preclinical WDI
Undisclosed indication Preclinical WDI

PNC1

Cell Target: photoreceptors

Retinitis Pigmentosa Preclinical

RND1

Cell Target: hypoimmune iPSC

Undisclosed indication Preclinical

ILT1

Cell

Type 1 Diabetes Preclinical

COR1

Cell

Fuchs Endothelial Corneal Dystrophy Preclinical
Bullous Keratopathy Preclinical
Corneal Endothelial Disease Preclinical

Technology platforms

AlloSCOPE

Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering platform enabling large-scale manufacture of allogeneic cell therapies from a single pluripotent cell line; supports differentiation across multiple programs including ophthalmology (OpRegen, COR1), spinal cord injury (OPC1), auditory neuropathy (ReSonance/ANP1), and islet cell therapy (ILT1); AlloSCOPE 5D variant targets higher-scale production with reduced manipulation via fully suspension-based bioreactor process.

Factor Bioscience Gene-Editing Platform · Factor Bioscience

Patented gene-editing platform used to engineer hypoimmune iPSC lines for cell and gene therapy candidates; Lineage holds exclusive option and license to develop edited hypoimmune cell lines into differentiated cell transplant product candidates across a wide range of diseases

Discontinued (1)

VAC2 — Non-Small Cell Lung Cancer · Company determined it was no longer going to pursue the VAC2 program and ceased development; VAC platform abandoned as of June 30, 2025

Biotech Distilled coverage (1)

2026-08-17 Lineage Cell Therapeutics (LCTX) — Scientific Deep Dive for OpRegen, OPC1, and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.